| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
1 company
Shanghai Fosun Pharmaceutical (group) Co., Ltd. is a 10% Owner at NATR. Recent filings cover 0 purchases and 8 sales.
Our model assigns Shanghai Fosun Pharmaceutical (group) Co., Ltd. a below-average insider score of 33/100, based on 8 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -16.7%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 27, 2025 | NATR Natures Sunshine Products Inc | 10% Owner | Sell | 2,854,607 | $11.46 | $32,713,796.22 | -100% | +12.0% | +45.0% | |
| Oct 15, 2024 | NATR Natures Sunshine Products Inc | 10% Owner | Sell | 2,300 | $13.02 | $29,946.00 | -3.5% | +8.0% | +15.0% | |
| Oct 14, 2024 | NATR Natures Sunshine Products Inc | 10% Owner | Sell | 10,895 | $13.33 | $145,188.82 | -2.5% | +7.2% | +13.1% |